As of Oct 26, 2026: Vertex Pharmaceuticals (VRTX) has a PDUFA date for povetacicept on Nov 30, 2026, in 35 days. Its Quality Score is 14. Scores as of 8:36 PM ET, 15 minutes behind.

VRTX FDA decision on Povetacicept

Vertex Pharmaceuticals · PDUFA date

PDUFA dateNov 30in 35 days Quality Score14Above Average

Cash runway–brings in cash

What the company said

“The U.S. FDA accepted the BLA submission for accelerated approval of povetacicept for adults with IgAN and assigned a PDUFA target action date of November 30, 2026.”

PDUFA date, Nov 30, 2026. As Vertex Pharmaceuticals stated in its 8-K of Aug 3, 2026 (the filing).

A PDUFA date is the day the FDA has said it aims to decide on a drug. The FDA can decide earlier, or extend its review, often by three months.

Tested. Our top-⁠scored stocks returned 2.2x the average stock over the next month. How we tested it

Get an alert before VRTX's FDA date

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

How VRTX's stock moved on its past FDA days, for Pro members. Pro members also see whether its cash lasts past Nov 30, and the members' FDA calendar with filters and optional alerts.

More on VRTX and the FDA calendar

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

The FDA calendar.